Dr. Reddy’s Laboratories Limited (NYSE:RDY) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued on Monday, AR Network reports. The firm currently has a $39.90 price objective on the stock. Zacks‘ target price suggests a potential upside of 3.21% from the stock’s previous close.
Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) opened at 38.66 on Monday. Dr. Reddy’s Laboratories Limited has a one year low of $31.17 and a one year high of $39.95. The stock has a 50-day moving average of $35. and a 200-day moving average of $36.36. The company has a market cap of $6.575 billion and a P/E ratio of 20.52.
Dr. Reddy’s Laboratories Limited (NYSE:RDY) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by $0.03. The company had revenue of $478.00 million for the quarter, compared to the consensus estimate of $551.40 million.
Separately, analysts at Jefferies Group raised their price target on shares of Dr. Reddy’s Laboratories Limited from $33.04 to $35.00 in a research note to investors on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $37.21.
Dr. Reddy’s Laboratories Limited (NYSE:RDY) is an integrated pharmaceutical company focused on providing medicines through its three business segments: Global Generics segment, Pharmaceutical Services and Active Ingredients (PSAI) segment and Proprietary Products segment.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.